mAb developer Oncobiologics launches CDMO business

By Melissa Fassbender

- Last updated on GMT

mAb developer Oncobiologics launches CDMO business
Oncobiologics has launched a CDMO business to provide mAb development and manufacturing capabilities in a small biotech company setting, says CFO.

Oncobiologics is a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing, and commercializing monoclonal antibody (mAb) therapeutics.

The company’s contract development and manufacturing (CDMO) business is based on its BioSymphony Platform, which also is used for in-house programs, and combines its capabilities with the India-headquartered firm Stelis Biopharma Private Limited​ to provide mammalian and microbial cell process development and bulk drug manufacturing.

The CDMO business also offers fill-finish services, including drug formulation development and lyophilization for biological products.

“Oncobiologics developed its CDMO platform to provide affordable, clinically important therapies,”​ said Larry Kenyon, Oncobiologics CFO.

“This platform enables the company to leverage its in-house mAb development and manufacturing capabilities in a small biotech company setting, resulting in a more efficient and timely process for bringing mAbs forward,”​ he told us.

In tandem with the CDMO launch, Oncobioglocis also has announced that is has entered into a Master Services Agreement (MSA) with Sonnet BioTherapeutics, a privately held development stage biopharmaceutical company.

Under the agreement – specific terms of which were not disclosed – Oncobiologics will provide its CDMO services for up to four drug product candidates over the next three years.

Pankaj Mohan, PhD, chairman and CEO of Oncobiologics said in a press release: “We believe this CDMO business, and the associated revenue, integrated with our ongoing efforts to develop our own proprietary innovative and biosimilar product candidates, will help us to reduce costs and improve efficiency to drive stockholder value."

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us

Products

View more

Webinars